<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "obinutuzumab inj VIAL">
<dose><value>100</value>
<value>900</value>
<value>1000</value>
</dose>
<route><value>IV</value>
</route>
<strength><value>25 mg/mL</value>
</strength>
<frequency><value>ONCE</value>
</frequency>
<instruction><value>Infuse dose diluted in 250 mL soidium chloride 0.9% at 25 mg/hour over 4 hours. Do not increase infusion rate. [Cycle 1 / Day 1]</value>
<value>Infuse dose diluted in 250 mL sodium chloride 0.9% at 50 mg/hour. If tolerated, the rate of the infusion may be escalated in increments of 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. [Cycle 1 / Day 2]</value>
<value>Infuse dose diluted in 250 mL sodium chloride 0.9% at 100 mg/hour. If tolerated, the rate of the infusion may be escalated in increments of 100 mg/hour every 30 minutes to a maximum of 400 mg/hour. [Cycle 1 / Day 8]</value>
<value>Infuse dose diluted in 250 mL sodium chloride 0.9% at 100 mg/hour. If tolerated, the rate of the infusion may be escalated in increments of 100 mg/hour every 30 minutes to a maximum of 400 mg/hour. [Cycle 1 / Day 15]</value>
<value>Infuse dose diluted in 250 mL sodium chloride 0.9% at 100 mg/hour. If tolerated, the rate of the infusion may be escalated in increments of 100 mg/hour every 30 minutes to a maximum of 400 mg/hour. [Cycles 2 to 6 / Day 1]</value>
</instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Chronic Lymphocytic Leukemia: HE416P protocol. Cycle 1, Day 1. Pretreatment with an intravenous corticosteroid, an oral analgesic/anti-pyretic and an inatihistamine drug is recommended.</value>
<value>Chronic Lymphocytic Leukemia: HE416P protocol. Cycle 1, Day 2. Pretreatment with an intravenous corticosteroid, an oral analgesic/anti-pyretic and an inatihistamine drug is recommended.</value>
<value>Chronic Lymphocytic Leukemia: HE416P protocol. Cycle 1, Day 8. Pretreatment with an intravenous corticosteroid, an oral analgesic/anti-pyretic and an inatihistamine drug is recommended.</value>
<value>Chronic Lymphocytic Leukemia: HE416P protocol. Cycle 1, Day 15. Pretreatment with an intravenous corticosteroid, an oral analgesic/anti-pyretic and an inatihistamine drug is recommended.</value>
<value>Chronic Lymphocytic Leukemia: HE417P protocol. Cycles 2 to 6, Day 1. Pretreatment with an intravenous corticosteroid, an oral analgesic/anti-pyretic and an inatihistamine drug is recommended.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=7842</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>